Navigation Links
ORNL's newly licensed neutron detector will advance human disease research
Date:9/6/2012

A neutron detector developed for studies focused on life science, drug discovery and materials technology has been licensed by PartTec Ltd. The Indiana-based manufacturer of radiation detection technologies is moving the technology developed at the U.S. Department of Energy's Oak Ridge National Laboratory toward the commercial marketplace.

The Neutron-Sensitive Anger Camera allows researchers to study a wider variety of crystalline structures, supporting studies in biology, earth science, geology, materials science and condensed matter physics.

"This ORNL detector system, developed for DOE's Spallation Neutron Source, can determine the time and position of the neutrons captured, enabling extremely accurate neutron time-of-flight measurements," said Yacouba Diawara of the Instrument and Source Design Division at ORNL.

The detector achieves very high efficiency, high timing and position resolution and low background noise at a reduced cost all characteristics that make it attractive for medical, biological and general scientific research.

"The detector is suited for biological samples because the protein crystals scientists are interested in are very small, about the size of a grain of sand," said Richard Riedel of the Instrument and Source Design Division at ORNL. "No other neutron detectors are suited for viewing these complex proteins at a pulsed neutron source."

The ORNL research team optimized an existing technology called the Anger Camera named after its inventor, Hal Oscar Anger by improving the detector's ability to view the atomic structure of crystals, such as those composed of protein macromolecules.

Previous neutron detectors struggled to resolve crystals smaller than 2 millimeters, but ORNL's system can clearly detect 1-millimeter and smaller crystals. This capability is important not only for biological crystals but also for small crystals that are subject to extremely high pressures using a
'/>"/>

Contact: Jennifer Brouner
brounerjm@ornl.gov
865-241-9515
DOE/Oak Ridge National Laboratory
Source:Eurekalert

Page: 1 2

Related biology news :

1. U of M researchers: Newly discovered genetic markers could signal colon cancer development
2. Newly discovered dinosaur implies greater prevalence of feathers
3. Newly discovered breast milk antibodies help neutralize HIV
4. Key proteins newly discovered form and function may provide novel cancer treatment target
5. Scientists advance field of research with publication of newly validated method for analyzing flavanols in cocoa
6. Newly found protein helps cells build tissues
7. Newly discovered foot points to a new kid on the hominin block
8. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
9. Newly released FDA draft guidelines for biosimilar drugs to be discussed at conference
10. Ultracold matter technology from CU and SRI International licensed to Boulders ColdQuanta
11. RIT leads development of next-generation infrared detectors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 Cellecta, Inc., a U.S.-based provider ... and biomarker discovery, announced the release of its ... all human protein coding genes. CRISPR technology enables ... gene,s function. Cellecta,s new Human Whole Genome CRISPR ... so that researchers can investigate in a single ...
(Date:7/23/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software ... ended June 30, 2015.  Revenue for the ... 33% compared to $6.8 million in the same quarter last ... $0.3 million, or $0.01 per diluted share, which compared to ... period a year ago.  Lower revenue and ...
(Date:7/21/2015)... OXFORD, Connecticut , July 21, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... the Wocket® smart wallet, announces that it has ... Tokenization System and Method. This ... that not only authorizes an account, but also ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... yourself with a blanket to stave off the shivers? ... help alleviate shivering in patients who have been cooled ... or dangerously high fevers are often cooled to reduce ... aid healing. Unfortunately, cooling induces a natural and familiar ...
... Tiny flying machines can be used for everything ... simply making smaller versions of planes and helicopters ... Carolina State University are mimicking nature,s small flyers ... maneuverability and performance. Small flyers, or micro-aerial ...
... from the British Antarctic Survey have collected individuals from a ... subjected them to increasing levels of water temperature to learn ... that they are likely to experience in the future. The ... really close to their upper temperature range, and that further ...
Cached Biology News:Robo-bats with metal muscles may be next generation of remote control flyers 2
(Date:7/30/2015)... ATLANTA , July 30, 2015 ... leaders to the 2015 AACC Annual Meeting & ... from July 26–30. The meeting showcased revolutionary ... improves the ability of healthcare providers to diagnose ... get effective medical treatment. As ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... The 2015 ... in-depth study on the current state of the global Propanol market with a focus ... CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, ...
(Date:7/30/2015)... CITY, Kan. , July 30, 2015 /PRNewswire/ ... ), a pet therapeutics company focused on the ... for companion animals, today announced that its strategic ... from a dose confirmation study of AT-016, an ... Aratana for the treatment of osteoarthritis pain in ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... for 15 minutes, couldn't imagine the influence the Internet, blogging, social ... these tools, everyone can have their 15 minutes - but just ... is about all anyone has time for these days, at least ... reminded of this after coming back from a near three-week holiday ...
... the lead cancer drug candidate of Madison's Quintessence Biosciences ... Food and Drug Aministration for being tested on cancer ... meeting of the American Association for Cancer Research , ... scale and applied in safe doses, the company announced. , ...
... Madison, Wis . - Mithridion, Inc ., a biopharmaceutical ... of Alzheimer's disease, has closed an additional $1.2 million of ... , ,The latest round of funding brings the total equity ... above the company's initial funding target. Mithridion will use the ...
Cached Biology Technology:On the Web, attention spans shrink, the need for value rises 2On the Web, attention spans shrink, the need for value rises 3Quintessence Biosciences advances cancer drug 2Alzheimer's drug developer lands $1.2M in venture funding 2Alzheimer's drug developer lands $1.2M in venture funding 3
Peptide-affinity Purified Polyclonal Antibody to Histamine H2 Receptor...
Peptide-affinity Purified Polyclonal Antibody to Retinoic Acid-Induced 3 (RAI3/RAIG1)...
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
...
Biology Products: